Announcement on Implementation of the 2nd Share Repurchase Cancellation and Share Capital Changes
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Announcement on Implementation of the 2nd Share Repurchase Cancellation and Share Capital Changes
Filed with SSE · · 3 pages · Chinese
Release
Zhejiang Hisun Pharmaceutical Co., Ltd. on 6ix
Earlier from Zhejiang Hisun Pharmaceutical
- Announcement on Obtaining "Notice of Approval for Marketing Application of Chemical APIs" for Finerenone API
- Announcement on Implementation of Dividend Distribution for 2025
- Announcement on Obtaining Drug Registration Certificate
- Announcement on Outline of Reception Day for Investors
- Announcement on Resolutions of the 2025 Annual General Meeting
Later from Zhejiang Hisun Pharmaceutical
- Announcement on Obtaining "Notice of Approval for Marketing Application of Chemical APIs" for Letermovir API
- Announcement on the Veterinary Drug Product Approval Number Obtained by a Subsidiary
- Announcement on the Signing of an Exclusive Product Licensing and Cooperation Agreement
- Notice on Convening the 2nd Extraordinary General Meeting in 2026
- Announcement on Expected Increase in Semi-annual Performance for 2026
Follow Zhejiang Hisun Pharmaceutical into a list and get an email when it puts out news.
Follow Zhejiang Hisun Pharmaceutical